(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 1.18% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.8%.
Charles River Laboratories International's revenue in 2025 is $4,028,615,000.On average, 5 Wall Street analysts forecast CRL's revenue for 2025 to be $195,416,262,224, with the lowest CRL revenue forecast at $193,764,339,125, and the highest CRL revenue forecast at $196,462,998,576. On average, 6 Wall Street analysts forecast CRL's revenue for 2026 to be $200,435,025,668, with the lowest CRL revenue forecast at $193,538,938,190, and the highest CRL revenue forecast at $204,199,418,143.
In 2027, CRL is forecast to generate $213,888,213,366 in revenue, with the lowest revenue forecast at $211,075,180,166 and the highest revenue forecast at $216,664,335,933.